In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today and set a price target of ...

William Blair analyst Sami Corwin maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today. The company’s shares closed ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Learn more about whether Alvotech or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.